Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Capital Expenditures (2016 - 2023)

Avalo Therapeutics' Capital Expenditures history spans 8 years, with the latest figure at $158000.0 for Q1 2023.

  • For Q1 2023, Capital Expenditures changed N/A year-over-year to $158000.0; the TTM value through Dec 2023 reached $158000.0, up 66.32%, while the annual FY2023 figure was $158000.0, 66.32% up from the prior year.
  • Capital Expenditures reached $158000.0 in Q1 2023 per AVTX's latest filing, up from $95000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $165969.0 in Q1 2019 to a low of $2.0 in Q4 2019.
  • Average Capital Expenditures over 5 years is $69101.3, with a median of $72000.0 recorded in 2020.
  • The largest YoY upside for Capital Expenditures was 1256.15% in 2019 against a maximum downside of 100.0% in 2019.
  • A 5-year view of Capital Expenditures shows it stood at $2.0 in 2019, then surged by 3149900.0% to $63000.0 in 2020, then tumbled by 82.54% to $11000.0 in 2021, then skyrocketed by 763.64% to $95000.0 in 2022, then soared by 66.32% to $158000.0 in 2023.
  • Per Business Quant, the three most recent readings for AVTX's Capital Expenditures are $158000.0 (Q1 2023), $95000.0 (Q3 2022), and $11000.0 (Q4 2021).